PolyU-developed Liverscan to launch in China, enabling mobile, non-invasive assessment of liver fibrosis

Liverscan, a palm-sized real-time B-mode ultrasound imaging guided system for liver fibrosis assessment developed by Prof. ZHENG Yongping, Director of the Research Institute for Smart Ageing (RISA), and his research team, will soon be introduced to the mainland Chinese market. The technology marks a major step in promoting the precise prevention and effective diagnosis of liver diseases in China.

Liver fibrosis is a common condition of chronic liver inflammation, which may lead to cirrhosis, loss of liver function or cancer. Liver biopsy, which has been the gold standard in the diagnosis of liver diseases, requires puncturing the skin of patients’ abdomen using needles and collecting a small sample of liver tissues. Liverscan provides a novel, non-invasive technology for liver fibrosis assessment.

Liverscan was developed after five years of development by the team based on PolyU’s related research results and patents. During the period, the team obtained the supports from Incu-bio incubation program of Hong Kong Science and Technology Park, Technology Start-up Support Scheme for Universities, and other funds.  Prof. Zheng founded Eieling Technology Limited, a PolyU-supported start-up, together with former and current team members, to develop, manufacture and market Liverscan. At present, Liverscan equipment is being trialled among some hospitals and medical examination centres in Hong Kong, as well as some top hospitals in mainland China.

Online coverage:

ifeng.com - https://polyu.me/4521I9o